ArticleJournal for immunotherapy of cancer2026
Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SPP1Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundB-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial clinical benefit in relapsed/refractory multiple myeloma (R/R MM). Nonetheless, immune escape and therapeutic resistance remain major challenges, and the molecular features of residual disease have not been fully elucidated.
methodsSingle-cell RNA sequencing (scRNA-seq) was applied to paired bone marrow samples collected before and after BCMA CAR-T treatment to characterize treatment-persistent myeloma cells. Functional validation involved in vitro co-culture assays, genetic perturbation, and in vivo xenograft modeling. CD74 inhibition was performed using the anti-CD74 monoclonal antibody milatuzumab.
resultsResidual myeloma subpopulations were identified with upregulated CD74 and migration inhibitory factor (MIF) expression. Exposure to BCMA CAR-T cells induced CD74 expression and MIF secretion in MM cells. CD74 overexpression enhanced proliferation and apoptosis resistance, while CD74 knockdown impaired cell viability. In an in vivo xenograft model, CD74 blockade synergized with BCMA CAR-T cells to reduce tumor burden, prolong survival, and suppress CD74 expression. The MIF-CD74/CD44 axis was implicated in sustaining residual disease under immune pressure.
conclusionsCD74 contributes to immune escape and CAR-T resistance in R/R MM. Therapeutic targeting of CD74 enhances BCMA CAR-T efficacy and may offer a viable combinatorial strategy to overcome resistance in R/R myeloma. TRIAL REGISTRATION NUMBER: ChiCTR2000040368.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.